Caribou's Off-the-Shelf Cancer Therapy Shows Promise, But Competition Looms for Biotech Startup
-
Caribou Biosciences' stock could skyrocket if its off-the-shelf cancer therapy CB-010 continues to produce impressive clinical trial results. It shrank tumors in 15 out of 16 lymphoma patients.
-
CB-010 is the first off-the-shelf CD19 therapy without PD-1. Early data looks competitive against autologous cell therapies like Yescarta.
-
Caribou's market cap is only $401 million despite CB-010's potential peak sales of over $1 billion. The stock is down 46% from its peak this summer.
-
Competition is stiff in allogenic cell therapies. More data is needed to show CB-010's long-term outcomes compete with autologous treatments.
-
Caribou is burning cash as it develops 3 candidates. It could be years before approved treatments generate revenue. The stock is high risk despite huge upside potential.